An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigin ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
In my last published opinion piece on this page, titled lsquo;A Wise Hedgehog Never Keeps a Single Hole Outlet, rsquo; I n I ...
For people who don't identify with neurotypicality or neurodivergence, what do we do? In keeping with today's day and age, ...
A Durham biotechnology firm with ties to UNC has a new CEO. STORY HIGHLIGHTS A Durham biotechnology firm has appointed new leadership as the firm tries to develop a new approach of treating ...